Aldebaran Capital’s Aclaris Therapeutics ACRS Stock Holding History

Aldebaran Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.96M	Sell	936,731 -10,431	-1%	-$46.5K	3.72%	9
2026 Q1	$3.55M	Sell	947,162 -7,100	-0.7%	-$24K	2.72%	11
2025 Q4	$2.87M	Sell	954,262 -33,436	-3%	-$84.5K	2.58%	12
2025 Q3	$1.88M	Sell	987,698 -6,000	-0.6%	-$10.5K	1.72%	18
2025 Q2	$1.41M	Sell	993,698 -14,260	-1%	-$19.3K	1.39%	18
2025 Q1	$1.54M	Sell	1,007,958 -9,000	-0.9%	-$19.2K	1.46%	19
2024 Q4	$2.52M	Sell	1,016,958 -26,194	-3%	-$65.2K	2.4%	13
2024 Q3	$1.2M	Buy	1,043,152 +185,000	+22%	+$227K	1.1%	20
2024 Q2	$944K	Buy	+858,152	New	+$1.01M	0.88%	21

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Aldebaran Capital's ACRS Position: Q2 2026 in Review

Aldebaran Capital reduced its Aclaris Therapeutics (ACRS) stake by 1.1% in Q2 2026, selling an estimated $46.5K and leaving 936,731 shares worth $4.96M. The position accounts for 3.72% of the portfolio, ranked #9.

Aldebaran Capital first reported a position in ACRS in Q2 2024 and has held it in 9 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Aldebaran Capital held 936,731 shares of Aclaris Therapeutics worth $4.96M as of Q2 2026.
Aldebaran Capital sold 10,431 Aclaris Therapeutics shares in Q2 2026, an estimated $46.5K.
Aclaris Therapeutics made up 3.72% of Aldebaran Capital's portfolio in Q2 2026, its #9 holding.
Aldebaran Capital first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 9 quarters since.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Aldebaran Capital's 13F filing for Q2 2026, filed 14 Aug 2026.